Conversations with CEI20 Marras 2025

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV. Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions.

On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY. She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care. Alex currently provides clinical leadership for HIV treatment and prevention programs.

Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content:

PrEP to Prevent HIV and Promote Sexual Health
University of Liverpool HIV Drug Interactions Checker (website and app)
CEI Line: 1-866-637-2342
https://ceitraining.org/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(70)

Updates on HSV Infection

Daniela DiMarco, MD, MPH is joined by guest speaker Valeria Cantos, MD for this episode of “Conversations with CEI.” Dr. Valeria Cantos is an Associate Professor at the Division of Infectious Diseases...

27 Elo 22min

Beyond the Script: Applying Harm Reduction Principles in Practice

Communication and relationship building are key approaches to harm reduction that focus on meeting people where they are. Both rely on shifting away from stigma and bias to create a safe, open dialogu...

13 Elo 46min

Cardiovascular Risk in People with HIV: New Risk Equations, New Guidelines, and Who Gets a Statin

The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline recommends statin therapy for primary prevention of ASCVD for all people living with HIV (PLHIV) aged 40 to 75 years, independently of their tradit...

23 Heinä 17min

Best of the Best: Practice-Changing Papers in STI Care from 2025

Hosts Margie Urban, MD, and Daniela DiMarco, MD, MPH, are joined by Jason Zucker, MD. Dr. Zucker is an Assistant Professor of Medicine at the Columbia University Irving Medical Center and is also the ...

9 Heinä 21min

Compassion, Choice and Curiosity: Harm Reduction in Practice

Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. It is also a movement for social justice build on a belief in, and respect f...

25 Kesä 20min

Closer to a Cure? New HIV Cure Research from Stem Cell Transplants to CAR-T Cell Therapy

Two recent studies have shown remarkable advances in HIV cure research: (1) a Norwegian man who achieved long-term HIV remission after a stem cell transplant from his brother and (2) a Phase 1 trial t...

11 Kesä 10min

ASSETS-NY – Anal Dysplasia Screening, Surveillance, Education and Treatment Services of NY

Host Marguerite Urban, MD is joined by William DeWitt, MD, Clinical Director of Anal Health in Primary Care at Northwell Health, to discuss a new coalition forming in New York City about anal dysplasi...

28 Touko 22min

Introducing Point-of-Care Testing for Hepatitis C

New York State’s Hepatitis C Dashboard shows that in 2023, 4,783 people were newly diagnosed with HCV in the state, an 8% decrease from 2022. Incidence also decreased, with the rate of new HCV infecti...

14 Touko 21min